Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The new company is focused on the development of first-in-class therapies for the treatment of inflammatory disorders with an initial target indication of the prevention of postoperative delirium.
Lead Product(s): Undisclosed
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Catalys Pacific
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 16, 2020